WILEX AG plans change on the Supervisory Board
| PDF Download
- Andreas Krebs will step down from the Supervisory Board at his own request
- Supervisory Board to have five members in future
Munich, Germany, 6 April 2016 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced its plan to reduce the number of Supervisory Board members from six to five.
Long-standing member Andreas Krebs will step down from the Supervisory Board at his own request for professional reasons after this year’s Annual General Meeting. Mr Krebs has been a member of the Supervisory Board of WILEX AG since 2010. Both the Supervisory Board and the Executive Management Board accept his decision with regret and thank him for his active support of the company.
“On behalf of the WILEX Supervisory Board I would like to thank Mr Andreas Krebs for his valuable contribution to the company’s continued development,” said Professor Christof Hettich, Chairman of the Supervisory Board of WILEX AG. “Our collaboration on the Supervisory Board was constructive and cooperative at all times. We very much regret that Mr Krebs will be leaving us.”
The Company will avail itself of the new opportunities offered by German stock corporation law and propose to the Annual General Meeting to reduce the number of Supervisory Board members. The required amendment to the Articles of Association will be presented to the Annual General Meeting for approval on 13 May 2016. The agenda of the AGM will be published in the Federal Gazette on 6 April 2016.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which discontinued all clinical development activities at its Munich site and now exercises a holding function as the Group parent. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX has the diagnostic and therapeutic drug candidates REDECTANE® and RENCAREX®, which are available for out-licensing and further development in Phase III for external partners. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.
Tel.: +49 (0)89-41 31 38-29
Grillparzerstr. 18, 81675 Munich, Germany
MC Services AG
Katja Arnold (CIRO)
Executive Director & Partner
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.